Contact
Please use this form to send email to PR contact of this press release:
Recce Pharmaceuticals Announces RECCE® Compounds Selected by CSIRO/Doherty Institute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral Screening Program
TO: